Business Description
Poolbeg Pharma PLC
ISIN : GB00BKPG7Z60
Share Class Description:
POLBF: Ordinary SharesTotal Employee Number:
15Description
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.87 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year FCF Growth Rate | 7.2 | |||||
3-Year Book Growth Rate | -31.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.94 | |||||
9-Day RSI | 49.58 | |||||
14-Day RSI | 57.31 | |||||
3-1 Month Momentum % | 3.83 | |||||
6-1 Month Momentum % | 46.09 | |||||
12-1 Month Momentum % | 47.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.17 | |||||
Quick Ratio | 6.17 | |||||
Cash Ratio | 5.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.7 | |||||
Shareholder Yield % | -8.35 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -57.32 | |||||
ROA % | -52.49 | |||||
ROIC % | -246.55 | |||||
3-Year ROIIC % | -1676.38 | |||||
ROCE % | -60.35 | |||||
Moat Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 9.5 | |||||
Price-to-Tangible-Book | 9.5 | |||||
EV-to-EBIT | -6.73 | |||||
EV-to-Forward-EBIT | -7.06 | |||||
EV-to-EBITDA | -6.79 | |||||
EV-to-Forward-EBITDA | -7.06 | |||||
EV-to-FCF | -8.32 | |||||
| Price-to-Net-Current-Asset-Value | 9.5 | |||||
| Price-to-Net-Cash | 9.5 | |||||
Earnings Yield (Greenblatt) % | -14.86 | |||||
FCF Yield % | -10.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:POLBF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Poolbeg Pharma PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.013 | ||
| Beta | -1.0094 | ||
| 3-Year Sharpe Ratio | -0.05 | ||
| 3-Year Sortino Ratio | -0.07 | ||
| Volatility % | 56.95 | ||
| 14-Day RSI | 57.31 | ||
| 14-Day ATR ($) | 0.002421 | ||
| 20-Day SMA ($) | 0.093293 | ||
| 12-1 Month Momentum % | 47.83 | ||
| 52-Week Range ($) | 0.042 - 0.1154 | ||
| Shares Outstanding (Mil) | 705.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Poolbeg Pharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Poolbeg Pharma PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-09-29 | In 96 days | ||
| General meeting for 2025 | 2026-06-09 11:00 | 0.12 (+0.00%) | ||
| Annual report for 2025 | 2026-05-07 | 0.06 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-28 | 0.06 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-29 | 0.04 (+0.00%) | ||
| General meeting for 2024 | 2025-06-23 12:00 | 0.04 (+0.00%) | ||
| Annual report for 2024 | 2025-05-27 | 0.04 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-05-20 | 0.12 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-09-18 | 0.15 (+0.00%) |
Show
Entries
Poolbeg Pharma PLC Frequently Asked Questions
What is Poolbeg Pharma PLC(POLBF)'s stock price today?
The current price of POLBF is $0.10. The 52 week high of POLBF is $0.12 and 52 week low is $0.04.
When is next earnings date of Poolbeg Pharma PLC(POLBF)?
The next earnings date of Poolbeg Pharma PLC(POLBF) is 2026-09-29 Est..
Does Poolbeg Pharma PLC(POLBF) pay dividends? If so, how much?
Poolbeg Pharma PLC(POLBF) does not pay dividend.
Guru Commentaries on OTCPK:POLBF
No articles.
Press Release
Articles on Poolbeg Pharma PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers